Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial.

Safiglipron, an oral GLP-1 receptor agonist, achieves non-inferiority and potential superiority to dapagliflozin in reducing HbA1c in type 2 diabetes patients.

• Why it matters: Effective oral treatments for type 2 diabetes are limited, and current options often require injections or strict dietary restrictions, highlighting the need for more accessible therapies.
• What they did: A phase 3 trial involving 810 adults compared three doses of safiglipron with dapagliflozin over 32 weeks, assessing changes in HbA1c, weight, and safety outcomes.
• The result: All doses of safiglipron met non-inferiority criteria, with the 90 mg dose showing superiority in HbA1c reduction, and it also improved weight and glucose control, supporting its use as an oral treatment option.